

Human *CLP1* Mutations Alter tRNA Biogenesis, Affecting Both Peripheral and Central Nervous System Function

Ender Karaca,^{1,21} Stefan Weitzer,^{2,21} Davut Pehlivan,^{1,21} Hiroshi Shiraishi,^{2,21} Tasos Gogakos,³ Toshikatsu Hanada,^{2,20} Shalini N. Jhangiani,⁴ Wojciech Wiszniewski,¹ Marjorie Withers,¹ Ian M. Campbell,¹ Serkan Erdin,⁵ Sedat Isikay,⁶ Luis M. Franco,^{1,7} Claudia Gonzaga-Jauregui,¹ Tomasz Gambin,¹ Violet Gelowani,¹ Jill V. Hunter,⁸ Gozde Yesil,⁹ Erkan Koparir,¹⁰ Sarenur Yilmaz,¹¹ Miguel Brown,³ Daniel Briskin,³ Markus Hafner,³ Pavel Morozov,³ Thalia A. Farazi,³ Christian Bernreuther,¹² Markus Glatzel,¹² Siegfried Trattning,¹³ Joachim Friske,¹³ Claudia Kronnerwetter,¹³ Matthew N. Bainbridge,⁴ Alper Gezdirici,¹⁰ Mehmet Seven,¹⁰ Donna M. Muzny,⁴ Eric Boerwinkle,^{4,14} Mustafa Ozen,¹⁰ Baylor Hopkins Center for Mendelian Genomics, Tim Clausen,¹⁵ Thomas Tuschl,³ Adnan Yuksel,¹⁰ Andreas Hess,^{16,17} Richard A. Gibbs,^{1,4} Javier Martinez,^{2,*} Josef M. Penninger,^{2,*} and James R. Lupski^{1,4,18,19,*}

¹Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA

²Institute of Molecular Biotechnology (IMBA) of the Austrian Academy of Sciences, 1030 Vienna, Austria

³Howard Hughes Medical Institute, Laboratory of RNA Molecular Biology, Rockefeller University, New York, NY 10065, USA

⁴Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA

⁵Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA 02114, USA

⁶Gaziantep Children's Hospital, Gaziantep 27560, Turkey

⁷Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA

⁸Department of Pediatric Radiology, Texas Children's Hospital, Houston, TX 77030, USA

⁹Department of Medical Genetics, Bezmialem University, Istanbul 34093, Turkey

¹⁰Department of Medical Genetics, Cerrahpasa Medical School of Istanbul University, Istanbul 34098, Turkey

¹¹Istanbul Medeniyet University, Faculty of Medicine, Department of Medical Genetics, Istanbul 34730, Turkey

¹²Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany

¹³Department of Radiology, MR Center of Excellence, Medical University of Vienna, Vienna 1090, Austria

¹⁴Human Genetics Center, University of Texas Health Science Center at Houston, Houston, TX 77030, USA

¹⁵Institute of Molecular Pathology (IMP), 1030 Vienna, Austria

¹⁶Institute for Experimental Pharmacology, Friedrich-Alexander University Erlangen-Nuremberg, 91054 Erlangen, Germany

¹⁷Campus Support Facility (CSF), Vienna BioCentre, Vienna 1030, Austria

¹⁸Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA

¹⁹Texas Children's Hospital, Houston, TX 77030, USA

²⁰Medical Innovation Center, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan

²¹Co-first author

*Correspondence: javier.martinez@imba.oeaw.ac.at (J.M.), josef.penninger@imba.oeaw.ac.at (J.M.P.), jlupski@bcm.edu (J.R.L.)
<http://dx.doi.org/10.1016/j.cell.2014.02.058>

SUMMARY

CLP1 is a RNA kinase involved in tRNA splicing. Recently, *CLP1* kinase-dead mice were shown to display a neuromuscular disorder with loss of motor neurons and muscle paralysis. Human genome analyses now identified a *CLP1* homozygous missense mutation (p.R140H) in five unrelated families, leading to a loss of *CLP1* interaction with the tRNA splicing endonuclease (TSEN) complex, largely reduced pre-tRNA cleavage activity, and accumulation of linear tRNA introns. The affected individuals develop severe motor-sensory defects, cortical dysgenesis, and microcephaly. Mice carrying kinase-dead *CLP1* also displayed microcephaly and reduced cortical brain volume due to the enhanced cell death of neuronal progenitors that is associated with reduced numbers of cortical neurons. Our data elucidate a

neurological syndrome defined by *CLP1* mutations that impair tRNA splicing. Reduction of a founder mutation to homozygosity illustrates the importance of rare variations in disease and supports the clan genomics hypothesis.

INTRODUCTION

In order to translate genomic information, tRNAs undergo essential posttranscriptional modifications, including chemical alterations, excision of introns followed by exon ligation, removal of 5' leader and 3' trailer sequences, and CCA addition (Phizicky and Hopper, 2010). Although tRNA synthesis and processing are essential to all cells, mutations in genes involved in tRNA transcription and maturation appear to preferentially affect the function of neurons. There is an emerging class of neurological disorders resulting from abnormal tRNA biogenesis. Mutations in genes encoding various aminoacyl tRNA synthetases result

in Charcot-Marie-Tooth neuropathy (*GARS*, *KARS*, *YARS*, *AARS*, and *HARS*) (Antonellis et al., 2003; Jordanova et al., 2006; Lee et al., 2006; McLaughlin et al., 2010; Vester et al., 2013), spastic ataxia with leukoencephalopathy (*MARS2*) (Bayat et al., 2012), distal spinal muscular atrophy (*GARS*) (Antonellis et al., 2003), or pontocerebellar hypoplasia type 6 (PCH6) (*RARS2*) (Edvardson et al., 2007). Another distinct group of disorders due to abnormal tRNA maturation is pontocerebellar hypoplasias associated with defects in genes encoding subunits of the tRNA-splicing TSEN complex, including mutations in *TSEN2*, *TSEN34*, and *TSEN54* (Budde et al., 2008; Cassandrini et al., 2010).

CLP1 was the first mammalian RNA kinase to be discovered (Weitzer and Martinez, 2007). We have recently shown that CLP1 acts in concert with the TSEN complex to remove introns present within the anticodon loop of numerous pre-tRNAs (Hanada et al., 2013). *Clp1* kinase-dead (*Clp1^{K/K}*) mice exhibit a progressive loss of spinal motor neurons associated with axonal degeneration in peripheral nerves, denervation of neuromuscular junctions, ultimately resulting in impaired motor functions, muscle weakness, paralysis, and fatal respiratory failure (Hanada et al., 2013). Human *CLP1* mutations have not been reported, and it is not known whether such mutations would also affect the human nervous system. Here, we report the identification of a human *CLP1* mutation that impairs tRNA splicing in vitro and causes a neurological syndrome involving both the central nervous system (CNS) and peripheral nervous system (PNS). All five families share a haplotype of common variants surrounding *CLP1*, supporting the notion that clan genomics contributed to the molecular pathology of disease in this lineage (Lupski et al., 2011).

RESULTS



A Neurological Syndrome Defined by *CLP1* Mutations in Humans

We studied patients with evidence of brain malformations and microcephaly who shared similar facial characteristics and global growth and also developmental delays, severe intellectual disabilities, and seizures refractory to treatment (Figures 1 and S1A available online). MRI revealed brain abnormalities of differing severities, including cortical dysgenesis marked by a simplified gyral pattern, particularly in the anterotemporal regions, mild or focal cerebellar vermal volume loss (BAB3520 and BAB4771), and thinning of the brain stem (BAB3520) (Figure 1). None of the 11 subjects studied could either ambulate or sit without support. They all have poor (10 to 15 s) head control, whereas the youngest patient (BAB5318; 6 months old) has not yet achieved head support. All patients had hypertonia and increased deep tendon reflexes. Electrophysiological studies revealed objective evidence for marked axonal sensorimotor neuropathies (Figure 2 and Table S1). In addition to these characteristic neurologic findings, careful clinical evaluation revealed that the patients exhibit facial features that appear distinctive, including high arched eyebrows, prominent eyes, long palpebral fissures and eyelashes, broad nasal roots, and hypoplastic alae nasi (Figure 1). Individual patient clinical details are provided in the Extended Experimental Procedures.

Targeted exome capture and whole-exome sequence (WES) of four affected individuals (BAB3401, 3402, 3421, and 3422), two from each nuclear family (HOU1338 and HOU1333, respectively) (Figures 1 and S1B), identified a homozygous c.G419A (p.R140H) (chr11:g.57,427,367 G > A [hg19], NM_006831.2) nonsynonymous substitution in the *CLP1* gene located on chromosome 11q12.1 (Figure 3A), in which mutations have not been associated previously with human disease. The *R140H* mutation has not been reported in the 1000 Genomes Project (<http://www.1000genomes.org>) or other large-scale exome sequencing projects, including the exome variant server, NHLBI GO Exome Sequencing Project (ESP) in Seattle, Washington (<http://evs.gs.washington.edu/EVS/>), and the “in-house”-generated exomes from more than 2,500 individuals at the Baylor College of Medicine (BCM) Human Genome Sequencing Center and BCM Whole Genome Laboratory Database (MGL; <http://www.bcm.edu/geneticlabs/>; with more than 1,000 individuals tested for diagnostic purposes) and the Atherosclerosis Risk in Communities Study (ARIC) Database (<http://drupal.csc.unc.edu/aric/>).

Because all four subjects from the original two kindreds undergoing exome sequencing presented with the same clinical syndrome, we hypothesized that *CLP1* mutations could cause a clinically distinguishable phenotype. We therefore re-analyzed our brain malformation cohort focusing on patients with similar CNS and PNS abnormalities and dysmorphic features and found three additional families with consanguinity; these subjects were unrelated to the former two families and had no known relation to each other. Using this phenotype-directed approach, Sanger sequencing of *CLP1* in the latter three families revealed the same *R140H* mutation in the homozygous state in all seven additional affected individuals, heterozygous carrier states in the parents and one unaffected male sibling, and homozygous wild-type status in one unaffected female sibling (HOU1380, HOU1926, and HOU1981) (Figures 1 and S1B), which is consistent with Mendelian recessive expectations.

None of the families in our study were previously aware of a relationship. All five families belong to the same ethnic group and reside in the same geographic area of Eastern Turkey. We therefore hypothesized that each family inherited the same mutation from a common ancestor in which this founder mutation occurred. To investigate this, we performed genome-wide SNP microarray analysis on 19 individuals. Pairwise identity-by-descent (IBD) estimation in PLINK (Purcell et al., 2007) matched reported familial relationships exactly but did not suggest recent common ancestry among these seemingly unrelated individuals (π -hat 0–0.04). Notably, all families share an 11.5 Mb haplotype in the *CLP1* region, which spans the centromere and is homozygous in the affected children (Figure 3A). For the last family (HOU1981; samples BAB4980 and BAB4981), the regions with absence of heterozygosity were experimentally determined from WES data that revealed homozygosity of the *CLP1* region in these two affected individuals (Figure 3A). Thus, we have identified a defined clinical syndrome with progressive central and peripheral nervous system defects in 11 affected children from five families, all of whom carry a homozygous *CLP1* *R140H* mutation.



(legend on next page)




Figure 2. Nerve Conduction Studies of Patients with *CLP1* Mutations

Left: results of sensory nerve conduction studies of the right median, right ulnar, and right sural nerves. Velocity and amplitude values are shown for individual patients as percentages of the minimum normal value (100%, dotted line). Abnormal values are highlighted in red hues. Values that were not recordable despite being tested are indicated as NR. Patients who did not have a given nerve tested are blank. Center: schematic showing the locations of the nerves tested. Right: results of motor nerve conduction studies of the right median, right common peroneal, and right tibial nerves. Patient numbers are indicated. See also [Table S1](#).

Molecular Modeling

Analysis of the human protein-protein interaction network revealed interactions between CLP1 and members of both mRNA 3' end processing and the tRNA-splicing TSEN complex ([Figure 3B](#)). In silico analyses suggest CLP1 is also connected to a number of human-disease-associated genes involved in DNA repair and cell-cycle control such as p53 and VRK1, as well as tRNA metabolism ([Figure 3B](#)). Analysis on the molecular evolution of the CLP1 mutation showed that the *R140H* amino acid change affects an arginine residue that is highly conserved from human to zebrafish ([Figure 3C](#)).

The CLP1 R140H mutation is predicted to be “damaging or disease causing” by different bioinformatics algorithms (PolyPhen-2, SNAP, SIFT, and Mutation Taster). Inspection of the yeast Clp1 crystal structure provides a possible explanation for this effect. In the yeast protein, the corresponding lysine residue (position 149) protrudes from the middle domain toward the N-terminal domain, determining the relative orientation of the two domains to each other ([Figure 3D](#)). Whereas an arginine, as seen in higher eukaryotes, may exert a similar organizing effect, a histidine side chain is too short to mediate this interaction.

We thus speculate that the R140H mutation results in an altered domain arrangement that is incompatible with binding potential partner proteins. We further predict that the R140H mutation should not abolish the RNA kinase activity of the enzyme, which is associated with the middle domain containing the catalytic site.

Perturbed CLP1-TSEN Complex Integrity Impairs Pre-tRNA Cleavage

Based on structure-prediction analysis, we investigated whether the R140H mutation affects CLP1 function. We first assayed RNA kinase activity of recombinant glutathione S-transferase (GST)-tagged wild-type CLP1, kinase-dead CLP1 (K127A mutation), and CLP1 with the R140H mutation expressed in *E. coli* ([Figures 4A](#) and [4B](#)) and FLAG-CLP1 complexes containing these CLP1 versions ectopically expressed and affinity purified from HEK293 cells ([Figure 4C](#)). Whereas kinase activity was abolished in the K127A mutants, as previously reported ([Weitzer and Martinez, 2007](#)), the R140H mutant protein retained kinase activity, albeit at a reduced level when compared to the wild-type CLP1 protein ([Figures 4B](#) and [4C](#)). We next tested for

Figure 1. Clinical Features and Brain MRI Images of Patients

Pedigrees of five nuclear families and morphological features of patients showing similar dysmorphic facial features, including high arched eyebrows and broad nasal roots. Midsagittal and axial views of cranial MRIs are also shown for each patient, revealing brain abnormalities of differing severities, including cortical dysgenesis marked by a simplified gyral pattern, particularly in the antero-temporal regions, shortening and thinning of the corpus callosum that is more prominent in the body segment, and vertical clivus in all patients. Also note focal volume loss of the cerebellar vermis in patient BAB4771 and mild cerebellar volume loss with thinning of the brain stem in patient BAB3520. See also [Figures S1A](#) and [S1B](#).




Figure 3. Allele Frequencies and Modeling of the *CLP1* Mutation

(A) B allele frequency plots for chromosome 11 in the five families. The 11 affected individuals share a common 11.5 Mb region of absence of heterozygosity (AOH) in the proximal long arm of the chromosome, including the *CLP1* gene. The location of the gene is marked with a red line. The shared region of AOH extends across the centromere to the proximal short arm of the chromosome. AOH figure for family HOU1981 was created from whole-exome data.

(B) Interactome of *CLP1* with subunits of the TSEN complex (green), components of the mRNA 3' end cleavage and polyadenylation complex (red), or genes involved in cell-cycle control and cell death such as p53, ATM1, BRCA1, MDM1, or VRK1 (blue).

(C) Sequence alignment of human *CLP1* with *CLP1* in other species. R140 is a conserved residue across all vertebrates.

(D) Crystal structure of the yeast *Clp1* proteins (Noble et al., 2007) illustrating its domain architecture. The highlighted Lys149 is positioned at the interface of the N-terminal and middle domains and is predicted to define the relative orientation of these domains. The zoomed-in image shows two glutamate residues of the N-terminal domain interacting with Lys149 that protrudes from the middle domain.

interactions between mutant *CLP1* and members of the TSEN complex. Intriguingly, the interaction of R140H *CLP1* with TSEN2, TSEN54, or TSEN34 was markedly reduced (Figure 4D).

In line with loss of *CLP1*-TSEN complex integrity, pre-tRNA cleavage activity of purified R140H *CLP1* was almost abolished (Figure 4E). Of note, the kinase-dead *CLP1* K127A mutation also




Figure 4. Biochemical Studies on Purified CLP1 R140H and Patient Fibroblasts

(A) Coomassie blue staining of purified recombinant GST-tagged wild-type CLP1, kinase-dead K127A CLP1, and the CLP1 R140H mutant protein. (B) RNA kinase assay using the indicated recombinant CLP1 versions showing that CLP1 R140H is still able to phosphorylate RNA. Recombinant proteins were incubated with an RNA duplex bearing a 5'-OH group and [³²P]Cp 3' end label at one strand for the indicated time points. RNA phosphorylation results in a migration shift after running the reaction products in a denaturing acrylamide gel. Note that RNA phosphorylation is completely abolished by the CLP1 K127A mutation. The panel is a representation of two technical replicates.

(C) RNA kinase assay using protein complexes containing FLAG-CLP1 wild-type, FLAG-CLP1 K127A, and FLAG-CLP1 R140H affinity purified from stably expressing HEK293 cells. HEK293 cells without expression of any tagged proteins served as a control. Assays were carried out with undiluted and 1:3-diluted eluates as indicated.

(D) Western blotting for TSEN components interacting with affinity-purified FLAG-CLP1 wild-type, FLAG-CLP1 K127A, and FLAG-CLP1 R140H.

(E) Pre-tRNA cleavage assay of affinity-purified FLAG-CLP1 wild-type, FLAG-CLP1 K127A, and FLAG-CLP1 R140H complexes incubated with an internally labeled intron-containing yeast pre-tRNA^{Phe}. Pre-tRNA processing was monitored by denaturing gel electrophoresis. Panels (C)–(E) are representative examples of two replicates.



(F) tRNA splicing assay of nuclear extracts of parental (BAB3845 and 3846) and patient (BAB3401 and 3402) fibroblasts incubated for the indicated time points with an internally labeled intron-containing yeast pre-tRNA^{Phe}. Pre-tRNA processing was monitored by denaturing gel electrophoresis.

(G and H) RNA kinase activity assay of nuclear (G) or cytoplasmic (H) extracts derived from parental and patient fibroblasts. Extracts were incubated with a 3' end-labeled 5' OH group containing RNA duplex for the indicated time points. RNA phosphorylation was monitored by denaturing gel electrophoresis. Panels (F)–(H) are representative examples of triplicate experiments. See also Figures S2A–S2C.

showed impaired interaction with TSEN proteins (Figure 4D), correlating with decreased pre-tRNA cleavage activity (Figure 4E) (Hanada et al., 2013).

We next isolated and established fibroblast cultures using skin biopsies from patients (BAB3401 and BAB3402) and their parents (BAB3845 and BAB3846) and prepared extracts equalizing for protein concentrations. In nuclear extracts from patient fibroblasts, there was only a minor detectable pre-tRNA cleavage activity (Figure 4F), and RNA kinase activity was reduced (Figure 4G). Because the CLP1-TSEN complex can be purified from cytoplasmic extracts of HeLa cells (Weitzer and Martinez, 2007), we also tested RNA kinase activity in the cytoplasm of patient fibroblasts. Here, the activity was reduced in comparison

to parental cells (Figures 4H). Another tRNA splicing-related biochemical activity—RNA ligation activity as assessed by an interstrand ligation assay in nuclear extracts (Popow et al., 2011)—did not correlate with the occurrence of the CLP1 R140H mutation in fibroblasts (Figure S2A). Western blot analysis confirmed the presence of CLP1, TSEN proteins, and the tRNA ligase HSPC117 in nuclear extracts of patient cells (Figure S2B). Although levels of CLP1 appeared reduced in nuclear extracts, CLP1 was present at similar levels in the cytoplasm of parental and patient cells (Figure S2C). Thus, our in vitro assays for analyzing purified protein complexes showed that the mutation does not abrogate kinase function but severely affects the association of CLP1 with components of the



BAB3402: Ile-TAT pre-tRNA (Chr19.tRNA10)

Figure 5. tRNA Analysis of Patient Fibroblasts

(A–C) Northern blot analyses of RNA from parental and patient fibroblasts. A probe complementary to the 5' exon of isoleucine-TAT and tyrosine-GTA tRNAs was used to detect mature and pre-tRNA species (top panels in [A] and [C]). Probes specifically directed against intron sequences were used to detect pre-tRNAs and tRNA introns of isoleucine-TAT Chr.19.tRNA10 (A, middle), Chr2.tRNA5 (B), and tyrosine-GTA Chr2.tRNA2 (C, middle; human February 2009 [hg19] genome assembly). U6 snRNA served as loading control (bottom in A and C). Asterisks denote truncated pre-tRNA species. See also [Figures S2D–S2G](#), [S3A](#), and [S3B](#).

(D) Example for an alignment of RNA-seq reads of patient (BAB3402) fibroblasts against precursor tRNA isoleucine-TAT (Chr19.tRNA10). Total RNA was subjected to partial alkaline hydrolysis prior to cloning and sequencing. Reads were aligned against an in-house curated list of mature and pre-tRNAs. The mature

(legend continued on next page)

TSEN complex, resulting in impaired pre-tRNA cleavage. This is consistent with impaired tRNA splicing observed in nuclear extracts from patient fibroblasts.

CLP1 R140H Mutant Fibroblasts Accumulate Introns Derived from Different tRNA Genes

We next isolated total RNA from parental and patient fibroblasts and performed Northern blot analysis using probes detecting tRNAs genomically encoded as intron-less versions (i.e., Met-CAT) or intron-containing versions (Ile-TAT, Tyr-GTA, Leu-CAA, and Arg-TCT). There was no significant difference in mature tRNA steady-state levels as exemplified by using probes against the exon junction and the 5' exon detecting multiple tRNAs of the same isotype, so-called pan-probes, in parental and patient fibroblasts (Figures 5A and 5C, top; Figures S2D and S2F). In addition, we performed RNA deep sequencing and subjected reads to a quantitative bioinformatics pipeline that failed to reveal consistent differences in global mature tRNA levels between both parental and patient cell lines (Table S2). We also performed Northern blot analysis to assess pre-tRNA levels using 5' exon pan-probes and intron probes detecting specific tRNA genes. We were not able to detect consistent global differences either in steady-state levels of pre-tRNAs between both parental and patient fibroblast cell lines or by comparing results obtained from either approaches (Figures 5A–5C [middle], S2D–S2E, and S2G and data not shown). Interestingly, both by Northern blotting and deep sequencing analysis, we reproducibly detected an accumulation of tRNA introns derived from three particular tRNA genes (Ile-TAT Chr19.tRNA10, Ile-TAT Chr2.tRNA5, and Tyr-GTA Chr2.tRNA2; Figures 5A and 5C [middle], 5B, and S3A–S3C and Table S3) in patient fibroblasts. Biochemical analysis using RNase R treatment that digests linear, but not circular, RNA revealed that Ile-TAT (Chr19.tRNA10) introns are linear (Figure S3D). Because these introns can be ligated to a 3' hydroxy-terminating RNA linker only upon prior 5' phosphorylation, we conclude that introns display a 5' hydroxy group (Figure S3E). Thus, our Northern analysis and deep sequencing data indicate that the *CLP1* R140H mutation in fibroblasts influences processing of pre-tRNAs, resulting in the accumulation of linear tRNA introns, whereas pre- and mature tRNA levels remain largely unaffected.

Microcephaly in *Clp1* Defective Mice

We recently reported progressive loss of motor neurons, axonal motor neuropathy, and muscle paralysis leading to death in kinase-defective *CLP1* K127A (*Clp1*^{K/K}) mutant mice (Hanada et al., 2013), a phenotype consistent with the observed impairment of motor functions in our patients, including features of sensorimotor axonal neuropathy. Of note, on a B6 background, all *Clp1*^{K/K} newborn mice die due to impaired innervations of the diaphragm, whereas, on a CBA/J background, *Clp1*^{K/K} mutant mice grow to adulthood and progressively lose spinal motor neurons and motor functions (Hanada et al., 2013). Given the

significant microcephaly noted in patients carrying the *CLP1* R140H mutation (Figures 1 and S1A), we wondered whether we had missed a brain phenotype in our mutant *Clp1*^{K/K} mice, also considering fundamental differences between human and rodent brain development (Lancaster et al., 2013).

To analyze potential microcephaly in *Clp1*^{K/K} mice, we first determined the brain sizes of control and viable adult *Clp1*^{K/K} mice on the CBA/J background. In all littermate pairs analyzed, we observed reduced brain weights in mice carrying a kinase-dead version of *Clp1* (Figures 6A and S4A). To confirm reduced brain weights, we used 15.2 Tesla MRI imaging. MRI-3D brain reconstructions showed significantly reduced brain volumes at 8, 12, and 28 weeks after birth, but not at 4 weeks after birth (Figures 6B and S4B). *Clp1*^{K/K} mice also did not show a continuous increase in the brain aspect ratio (Figure S4C), which describes the elongation of the brain during normal development. Moreover, using geometric structural analysis, we observed markedly reduced cortical thickness throughout the entire cortex (Figures 6B and S4D). This difference is particularly prominent in the frontal and somatosensory-motor areas of the cortex (see red and yellow areas in Figures 6B and S4D). The reduction of cortical thickness was confirmed histologically (Figures S4E and S4F).

Immunohistochemical analysis with antibodies against neuronal nuclear antigen (NeuN) to detect neurons showed normal cortical layering (Figure S5A). Importantly, in line with reduced brain size and reduced cortical thickness, we found reduced numbers of NeuN⁺ neurons in the neocortex of adult *Clp1*^{K/K} mice as compared to their wild-type littermate controls (Figure 6C). By contrast, microglial cells, as detected by immunostaining for ionized calcium binding adaptor molecule 1 (Iba-1), appeared to be increased in the neocortex of *Clp1*^{K/K} mice, albeit not to significant levels (Figures S5B and S5C). Numbers of glial fibrillary acidic protein (GFAP)-positive astrocytes were apparently not affected in the hippocampus (Figures S5D and S5E) or in the cortex (data not shown) of *Clp1*^{K/K} mutant mice. Of note, neuronal, microglial, and astrocyte numbers and distributions were not affected in the cerebellum of *Clp1*^{K/K} mice (Figures S5F–S5J, and data not shown); the cerebellar volume was also not affected in *Clp1*^{K/K} mutant mice as determined by MRI (Figure 6B and data not shown). Thus, similar to humans with *CLP1* R140H mutations, these data show that mice carrying kinase-dead *Clp1* mutation exhibit microcephaly, in particular due to reduced numbers of cortical neurons.

When we analyzed *Clp1*^{K/K} embryos on the lethal B6 mouse background, we did not observe significant total brain weight differences between wild-type and *Clp1*^{K/K} mice at embryonic day 16.5 (E16.5); however, *Clp1*^{K/K} mice showed significantly decreased brain weights at E18.5 and reduced brain sizes as determined by histology (Figures 7A and S6A–S6C). The results were confirmed using MRI showing comparable brain volumes at E16.5 (64.4 mm² for *Clp1*^{+/+} versus 62.3 mm² for *Clp1*^{K/K} embryos) and a 13.7% reduction in mutant embryos at E18.5 (95.9 mm² for *Clp1*^{+/+} versus 84.3 mm² for *Clp1*^{K/K} embryos)

tRNA (blue), the tRNA intron (orange), and the 5' leader and 3' trailer sequences (green) are shown. The frequency of each read is presented (count). All reads mapped uniquely to the identified positions. Upstream and downstream nucleotides with no sequencing evidence are shown in black. Vertical lines represent the relative frequency of binned, normalized read counts in log₂ increments. See also Figure S3C to compare the accumulation of intron reads relative to parental (BAB3846) fibroblasts.




Figure 6. Microcephaly in Adult Kinase-Defective *Clp1* Mice

(A) Scatterplots showing brain weights of *Clp1*^{+/+} and K127A mutant *Clp1*^{K/K} mice on the viable CBA/J background. The ages of mice at the time of analysis are indicated; matching ages correspond to littermate pairs.

(B) Surface renderings of bulbus olfactorius (dark blue), cortex (transparent green), hippocampus (yellow), and cerebellum (light blue) from MRI data sets of adult mice at 4-, 8-, and 28-week-old *Clp1*^{+/+} and *Clp1*^{K/K} littermate mice. The right panels additionally show for 28-week-old animals a pseudo-color-coded mapping of cortical thickness ranging from blue (0.0 mm) to increased thickness shown in red (2.5 mm).

(C) Immunohistochemical analysis with antibodies against NeuN to detect neurons in the cortex of 12-week-old littermate *Clp1*^{+/+} and *Clp1*^{K/K} mice. Left panels show representative images of NeuN⁺ neurons (green). Sections are also stained for neurofilament and counterstained with Hoechst 33342 to visualize nuclei (blue). Scale bars, 50 μ m. Right panel shows quantification (mean values $\pm$ SEM) of NeuN⁺ neuron numbers in the neocortex. $n = 6$ mice per genotype. * $p < 0.05$. See also Figures S4 and S5.

(Figure S6D). Moreover, in 3D whole-brain reconstructions using 15 Tesla MRI imaging, we also observed markedly reduced brain volumes at E18.5 but comparable brain volumes at E16.5 (Figures 7B and 7C). At E18.5, the main reduction in brain volume was observed in the cortex of *Clp1*^{K/K} mice, with additional significant reductions in the volume of the bulbus olfactorius, whereas the volumes of the cerebella were comparable between control and *Clp1*^{K/K} littermates (Figures 7B and S6E). Cortical thickness was comparable between E16.5 *Clp1*^{+/+} and *Clp1*^{K/K} embryos, but it was markedly reduced in E18.5 *Clp1*^{K/K} embryos as compared to their wild-type littermate controls (Figure 7B). Shape analysis of the brain geometry by principal component analysis (PCA) further revealed that, in the control, all three spatial axes increased significantly from E16.5 to E18.5, but in the *Clp1*^{K/K} embryos, the third PCA (dorso-ventral direction)

had even decreased, whereas the first PCA (anterior-posterior direction) and the second PCA (caudal-rostral direction) were apparently normal in the *Clp1*^{K/K} mice (Figure S6F), indicating impaired dorso-ventral expansion of the cortex. The latter is also reflected by the fact that only wild-type control brains exhibit a significant decrease in cortical roundness due to changes in brain geometry (Figure S6G). These data show that mice carrying a homozygous CLP1 K127A kinase-dead mutation exhibit impaired expansion of the brain cortex, resulting in microcephaly.

Similar to adult *Clp1*^{K/K} mice, mutant E18.5 embryos had reduced numbers of Tbr1⁺ neurons as compared to control littermates; at E16.5, the numbers of Tbr1⁺ neurons were comparable among control and *Clp1*^{K/K} embryos (Figures 7D, 7E, and S6H). Numbers and distributions of Iba-1⁺ microglial cells were

apparently not altered in E16.5 and E18.5 *Clp1*^{K/K} embryos (Figures S7A and S7B), nor did we observe any obvious alterations in GFAP⁺ astrocytes (Figure S7C). We also observed normal numbers of Pax6⁺ neuronal progenitor cells in E16.5 and E18.5 *Clp1*^{K/K} mice as compared to their littermate controls (Figures S7D–S7F). Numbers of proliferating cells as determined by Ki67 staining were also normal, albeit slightly reduced in E16.5, as well as E18.5 *Clp1*^{K/K} embryos (Figure S7G). Importantly, we detected a higher number of apoptotic cells throughout the brain of E16.5 and, in particular, E18.5 *Clp1*^{K/K} embryos (Figure 7F). To test whether neuronal progenitors are more susceptible to death in *Clp1* mutant embryos, we prepared neural precursor cells (NPCs) from E14.5 control and *Clp1*^{K/K} embryos. Importantly, *Clp1*^{K/K} neural precursor cells exhibited enhanced cell death in basal growth conditions (using EGF and FGF), under oxidative stress, as well as following growth factor withdrawal; this enhanced cell death could be blocked using the pan-caspase inhibitor zVAD, as well as the antioxidant N-acetyl-L-cysteine (NAC) (Figure 7G). These data indicate that *Clp1*^{K/K} embryos have normal numbers and proliferation of neuronal progenitors, but neuronal progenitor cells undergo enhanced cell death, resulting in reduced numbers of cortical neurons.

DISCUSSION

In this study, we provide genomic, genetic, and molecular modeling and biochemical and animal model evidence for the involvement of *CLP1* in a complex neurological phenotype that includes both the CNS and PNS. We identified the same homozygous rare variant, *R140H*, of the *CLP1* gene in 11 individuals affected with this neurological syndrome from five families using WES and candidate gene sequencing. Further genetic analysis revealed that these families share the same haplotype block encompassing the *CLP1* region. These data support the concept of clan genomics (Lupski et al., 2011) in that a rare variant in the population is concentrated in a lineage that introduced the variant, either by de novo mutation or by immigration and subsequent founder effect. In the patients identified here, the rare *R140H* mutation was reduced to homozygosity. Our genomic and genetic data indicate that a rare variant allele arose in a distant common ancestor, segregated through the generations, and was reduced to homozygosity by apparent consanguinity. Genomic approaches to rare variant detection in Mendelizing disease traits may eventually provide new insights into both the genetic and molecular basis of disease, as well as reveal unexpected consequences of dysfunction of basic biological processes such as RNA metabolism.

Our findings reveal cortical dysgenesis with predominant forebrain involvement by MRI and no overt evidence for midbrain or prominent cerebellar abnormalities. Our mouse studies support predominant cortical cellular apoptosis likely responsible for the uniform microcephaly observed during development in mice and postnatally in all human subjects with homozygous *R140H* alleles. A parallel study in this issue of *Cell* (Schaffer et al., 2014) reported *CLP1* mutation in association with a clinical phenotype of pontocerebellar hypoplasia; they also report a *R140H* founder mutation. In a zebrafish model organism study of *Clp1* mutation, they show TUNEL staining, revealing dramatic

increase specific to forebrain and hindbrain. Forebrain staining supports both our mouse and human findings in which predominant cortical involvement is observed.

Our data provide insights into the biology of disease, including cortical dysgenesis. Mutations in proteins involved in RNA modifications have been associated previously with preferentially or exclusively either CNS or PNS pathology. For instance, mutations in *EXOSC3*, *TSEN54*, *TSEN2*, and *TSEN34* are known to cause neurological phenotypes that manifest in the brain stem and cerebellum, causing Pontocerebellar hypoplasia (PCH) PCH1B, PCH2A, PCH4, PCH2B, and PCH2C, but little is known regarding potential PNS involvement, as the results of nerve conduction studies have not been reported (Budde et al., 2008; Renbaum et al., 2009; Wan et al., 2012). Conversely, mutations in tRNA synthetase genes, such as *GARS*, *KARS*, *YARS*, *AARS*, and *HARS*, are predominantly associated with Charcot Marie Tooth neuropathy, distal spinal muscular atrophy, and other PNS disorders without significant CNS involvement (Antonellis et al., 2003; Jordanova et al., 2006; Lee et al., 2006; McLaughlin et al., 2010; Vester et al., 2013).

Our biochemical experiments provide evidence that the *CLP1* R140H mutation impairs tRNA exon generation, most likely due to decreased interaction between mutant *CLP1* and the TSEN complex. Together with our previous study showing that a kinase-dead *Clp1* K127A mutation results in reduced pre-tRNA cleavage by affecting *CLP1*-TSEN complex integrity (Hanada et al., 2013), we propose that an intact *CLP1*-TSEN association is essential for efficient tRNA splicing. The fact that the *CLP1* R140H mutant shows RNA kinase activity but is unable to associate with TSEN components will support the need for future studies on modeling potential *CLP1*-TSEN interaction platforms that are, in contrast to the kinase-dead *CLP1* K127A mutation, uncoupled from its ATP binding and/or hydrolysis activity.

We further show that the global steady-state levels of mature tRNAs in fibroblasts are not influenced by the *CLP1* R140H mutation, suggesting the existence of backup mechanisms that ensure sufficient levels of mature tRNAs despite the undetectable pre-tRNA cleavage activity observed in nuclear extracts from patient cells. No obvious increase in general pre-tRNA levels was observed in patient fibroblasts, and therefore, it is unlikely that enhanced Pol III transcription of intron-containing tRNA genes could compensate for inefficient pre-tRNA cleavage. Analogous to the accumulation of 5' leader-exon tRNA fragments in cells and tissues of *Clp1*^{K/K} mice (Hanada et al., 2013), we detected increased levels of isoleucine and tyrosine tRNA introns in R140H patient fibroblasts. These introns are linear and harbor 5' OH groups, properties that are expected for a reaction product after pre-tRNA cleavage and prior to a potential 5' phosphorylation by *CLP1* (Weitzer and Martinez, 2007) or circularization by the tRNA ligase (Popow et al., 2011). Future work will have to address whether accumulation of linear introns is a consequence of a defective release from a TSEN complex in *CLP1* R140H patient cells, thus being not exposed to cellular nuclease activities. Further studies may also provide insights into whether generation of tRNA processing intermediates is a consequence of mutations in the *CLP1* gene and potential functions of these tRNA splicing byproducts.




Figure 7. Microcephaly in Kinase-Defective *Clp1* Embryos

(A) Brain weights and representative dorsal whole-brain views (insets) of *Clp1*^{+/+} control and *Clp1*^{K/K} E16.5 and E18.5 mouse embryos on the neonatal lethal C57BL/6 (B6) background.

(B and C) 3D brain evaluations via MRI. (B) Representative visualizations of individual E16.5 and E18.5 *Clp1*^{+/+} and *Clp1*^{K/K} mouse embryos on the B6 background. On top of an MRI slice iso-surface, 3D renderings are shown for the bulbus olfactorius (dark blue), cerebellum (light blue), and the cortex. The cortex is rainbow (legend continued on next page)

We demonstrated that mutations in *CLP1* impair functioning of neurons and lead to abnormalities of both the CNS and PNS. Our patients present with peripheral nerve dysfunction as evidenced by abnormal electrophysiological studies showing axonal neuropathy affecting both motor and sensory nerves. These observations were universal in the eight affected individuals with *CLP1* mutations for whom NCVs were assessed. Moreover, all patients exhibit global cortical dysgenesis and microcephaly, which is suggestive of global CNS dysfunction. Based on these human phenotypes, we speculated that our mutant mice carrying a kinase-inactivating *CLP1* mutation might also exhibit abnormalities of both the CNS and PNS. Indeed, using histological analyses and 3D reconstruction from MRI images, mice carrying a homozygous *CLP1* K127A kinase-dead mutation exhibit marked microcephaly, in particular due to reduced numbers of cortical neurons. Mechanistically, this phenotype appears to be progressive and can be attributed to enhanced apoptosis of neuronal progenitor cells at basal conditions and in response to oxidative stress and growth factor withdrawal. Whether additional mechanisms contribute to the observed microcephaly in mice and whether these uncovered mechanisms also extend to humans will need to be evaluated in future experiments. It is striking that the clinical presentation of patients with *CLP1* mutations is nearly identical to one we observed in patients with *VRK1* mutations (Gonzaga-Jauregui et al., 2013), especially in the neurological presentation (progressive weakness), brain imaging studies (cortical dysgenesis, microcephaly), and nerve conduction velocity (NCV) (axonal neuropathy). From our network analysis, *CLP1* and *VRK1* are molecular interactors, and it has been reported that *VRK1* can phosphorylate p53 (Valbuena et al., 2006, 2011). We recently reported that kinase-dead *CLP1* sensitizes motor neurons and fibroblasts to death following oxidative stress via a p53-mediated cell death pathway; genetic inactivation of p53 completely rescued the neonatal lethal phenotype of *Clp1^{K/K}* mice on a B6 background (Hanada et al., 2013). Thus, based on our published genetic data in mice (*Clp1^{K/K}*) now complemented by genomic approaches in human rare disease studies (*CLP1* and *VRK1*), it appears that the neurotoxic *CLP1*-p53 pathway we have identified in mouse is also conserved and operates in humans and is critical to neuron function.

EXPERIMENTAL PROCEDURES

Patients

This study was approved by the Institutional Review Board at Baylor College of Medicine, and informed consent was obtained from all subjects prior to

enrollment in the project. All subjects were evaluated by one or more pediatric neurologists and clinical geneticists experienced with brain malformation phenotypes. Genomic DNA was extracted from blood based on the manufacturer's protocol (QIAGEN Sciences).

Whole-Exome Sequencing

Four initial affected individuals (BAB3401, BAB3402, BAB3421, and BAB3422) underwent targeted whole-exome capture using the BCM HGSC Core design followed by Illumina HiSeq massively parallel sequencing through the Baylor-Hopkins Center for Mendelian Genomics (BHCMG) initiative. An average of 10 Gb of raw sequence data were produced and subsequently mapped and aligned to the reference human genome sequence GRCh37/Hg19 using the BWA algorithm with an average depth of coverage of 120× (median coverage = 91×); ~92% of the bases were covered at 20×. Variants were called and annotated using an in-house-developed bioinformatics pipeline. Analysis of variants was initially performed in search for shared variants between the pairs of affected siblings under a recessive model of inheritance and later filtered for high-frequency and commonly observed variants.

Sanger PCR Confirmation and Segregation Studies

To confirm the mutation detected by exome sequencing and to perform segregation analysis, standard PCR was carried out as previously described (Pehlivan et al., 2012) by using CLPF1: 5'-AGAGCTGACCCGAAACAAGA-3' and CLPR1: 5'-CCAGCTGAGAAAATGCAGTG-3' primers. Amplification products were electrophoresed on 0.8% agarose gels. PCR products were purified using ExoSAP-IT (Affymetrix, Santa Clara) and analyzed by standard Sanger di-deoxy nucleotide sequencing (DNA Sequencing Core Facility at Baylor College of Medicine, Houston).

Genome-wide Genotyping

To further investigate family relationships and the haplotype structure of variant alleles, we performed genome-wide SNP genotyping on Illumina HumanOmniExpress (families HOU1338 and HOU1333) and HumanOmni2.5 (families HOU1926 and HOU1380) microarrays (Illumina). Whole-genome amplification, fragmentation, hybridization, enzymatic single-base extension, slide staining, and washing were performed according to the manufacturer's instructions (Illumina). Microarrays were scanned on an Illumina iScan System. GenomeStudio software v2011.1 (Illumina) was used for SNP clustering, genotype calling, data intensity analysis, and the generation of the B allele frequency plots in Figure 3A. Copy number variation (CNV) partition was used for copy number and absence of heterozygosity analyses. For the last family (HOU1981; samples BAB4980 and BAB4981), B allele frequencies were determined from the whole exome data, i.e., by computing the variant/total reads ratio for each SNP. The regions with absence of heterozygosity were identified using in-house scripts in R language (<http://www.r-project.org>) and Circular Binary Segmentation algorithm implemented in DNACopy R package (Olshen et al., 2004).

Identity-by-Descent Estimation

PED and MAP files were exported from GenomeStudio and analyzed in PLINK. Because two different microarrays were used in the study, merged PED and MAP files were generated, which included only the 668,800 SNPs that were common to both arrays. Genotyping rate for this subset

color coded to illustrate the cortical thickness from 0 mm (blue) to 1.5 mm (red, more thick). (C) Quantification of brain volumes (mean values ± SEM) determined via MRI. n = 8.

(D) Representative images from immunohistochemical analysis with antibodies against Tbr1 to detect neurons in the cortical plate of *Clp1^{+/+}* control and *Clp1^{K/K}* E18.5 embryos on the B6 background. Scale bars, 50 μm.

(E) Quantification (mean values ± SEM) of Tbr1⁺ neuron numbers in the neocortex of *Clp1^{+/+}* control and *Clp1^{K/K}* E18.5 embryos on the B6 background. Of note, the area of Tbr1⁺ cells encompasses a region from the lateral ventricle to the brain surface (width of 300 pixels, ~100 μm). n = 8 mice per genotype.

(F) Quantification (mean values ± SEM) of cleaved Caspase 3⁺ cell numbers, indicative of apoptosis, in coronal sections of *Clp1^{+/+}* control and *Clp1^{K/K}* E16.5 and E18.5 embryos on the B6 background. n = 3 mice per genotype.

(G) Cell death of neuronal progenitors isolated from E14.5 *Clp1^{+/+}* and *Clp1^{K/K}* embryos. Cells were cultured with (+) or without (−) EGF/FGF (each 20 ng/ml) and challenged with H₂O₂ (100 μM). Death was determined by assaying for cleaved Caspase 3 and blocked using zVAD (100 μM) or NAC (10 mM). Data are shown as mean values ± SEM of triplicate cultures. *p < 0.05, **p < 0.01, and ***p < 0.001. N.S., not significant.

See also Figures S6 and S7.

of SNPs, after merging the data for the four families, was 0.99984. Heterozygous haploid (sex chromosome) SNPs were excluded. Linkage disequilibrium-based pruning was then performed, excluding SNP pairs with r^2 values > 0.2 . After LD-based pruning, the remaining 28,581 SNPs were used to estimate pairwise identity-by-descent metrics (171 pairwise comparisons for 19 individuals).

Bioinformatics

The functional impact of the p.R140H substitution was assessed by considering conservation scores from PhyloP (Siepel et al., 2006), GERP (Cooper et al., 1998), and LRT (Chun and Fay, 2009) and, additionally, functional prediction scores from PolyPhen-2 (Adzhubei et al., 2010), SNAP (Bromberg et al., 2008), SIFT (Kumar et al., 2009), and MutationTaster (Schwarz et al., 2010), which are computational algorithms that estimate the detrimental effect of nonsynonymous substitutions based on statistical and machine learning models. Graphical representations of molecular models were prepared with PyMol (The PyMOL Molecular Graphics System, Schrödinger).

OFC Calculations

WHO head circumference data are only available from birth to age 5 years. Therefore, we used head circumference data from the literature for boys and girls starting from birth to 18 years (Roche et al., 1987). For time points that were not available in the primary data, we interpolated the values for both mean and SD using the R statistical programming language (R Core Development Team).

Histology and Immunohistochemistry

Clp1^{K/K} mutant mice were generated as described (Hanada et al., 2013) and maintained according to institutional guidelines. Whole brains were fixed in 4% paraformaldehyde, washed in PBS, dehydrated, and paraffin embedded according to standard protocols. For all procedures, 2- to 5- μ m-thick coronal sections of formalin-fixed paraffin-embedded mouse brains were used. For hematoxylin and eosin staining (H&E), routine protocols were used. For immunohistochemical analysis, blocking of endogenous peroxidase activity was performed with 0.3% H_2O_2 for 15 min on deparaffinated sections at room temperature, followed by treatment in a microwave oven (750 W) for 15 min in 10 mM citrate buffer (pH 6.0) for antigen retrieval before applying primary antibodies. Then, the first antibody in blocking buffer (5% goat serum/45% Tris buffered saline [pH 7.6] [TBS]/0.1% Triton X-100 in antibody diluent solution [Zytomed]) was applied overnight at 4°C. The following antibodies were used: rabbit polyclonal anti-Iba-1 (Iba-1, Wako Chemicals), mouse monoclonal anti-GFAP (Dako), mouse monoclonal antibody against neuronal nuclear antigen (NeuN, Chemicon), mouse monoclonal anti-Calbindin D-28K antibody (Sigma-Aldrich), mouse monoclonal anti-Neurofilament 200 antibody (Sigma-Aldrich), rabbit polyclonal anti-Pax6 (Covance), rabbit polyclonal anti-Thr1 (Abcam), rabbit polyclonal anti-cleaved caspase 3 (Cell Signaling Technology), and anti-Ki67 (Novocastra). Histofine universal immunoperoxidase polymer and Histofine Mouse Stain Kit (Nichirei Biosciences) were applied after washing with TBS. The peroxidase reaction was detected using diaminobenzidine (Sigma-Aldrich) as chromogen. Counterstaining was performed using alum-hematoxylin. For immunofluorescence staining, Alexa Fluor 488 or 555 (Molecular Probes) was used as a secondary antibody with Hoechst 33342 for nuclear staining. Some quantifications were done using the public NIH Image J 1.46 software on comparable sections taken at the same, defined anterior-posterior level.

MRI

Clp1^{K/K} mutant mice and wild-type mice were analyzed using MRI. These data are published using an ultra-high-field 15.2 Tesla horizontal Biospec scanner (152/11, Bruker, Ettlingen). The magnet has a free bore of 110 mm and is equipped with actively shielded gradients (1,000 mT/m) and third-order shims. All scans were performed using a whole-body transmitter/receiver quadrature coil with an inner diameter of 35 mm. The SNR improvement of the high field allowed us to obtain from E16.5 and E18.5 mouse embryos 3D diffusion weighted spin echo sequences (TR/TE = 500/16.5 ms, 16 averages, b factor = 650 s/mm²) with FOV 12 × 12 × 8 mm with an imaging matrix 240 × 240 × 40 resulting in a spatial resolution of 50×50×200 μ m. The

same approach was taken to scan adult mouse brains, with the modification that the FOV (16 × 16 × 8 mm) and, consequently, the imaging matrix (320 × 320 × 40) had to be adjusted to keep the same resolution and total measurement time (NEX 9). For the adult brains, a b factor of 300 s/mm² resulted in better contrast of the different brain structures. For images of whole embryos, we used a 7T whole-body scanner. These images were acquired with a standard turbo spin echo sequence (TE 48 ms, TR 380 ms) with a voxel resolution of 78 × 78 × 500 μ m³ (J. Friske et al., 2012, ESMRMB, conference).

MRI Image Analysis

For each 3D image data set, the bulbus olfactorius, the cortex, the cerebellum and, for the adult brains, the hippocampus were manually segmented using the AMIRA software (V 5.5, VSG). Based on these segmentations, surface renderings of the individual segmented brain structures were displayed onto a representative horizontal MR slice at the ventral eye position using AMIRA visualization modules. The thickness of the cortex was determined at each vertex by computing the distance along the vertex normal to the normal's intersection with the closest triangle of the cortex. The resulting scalar field was surface mapped onto the surface rendering of the cortex. Geometric properties (volume, principal axes, and form factors) of each segmented brain structure were calculated using MagnAn (BioCom GbR).

Preparation of NPCs

Preparation of embryonic neuroepithelial cells containing neural precursor cells (NPCs) was performed as previously described (Shiraishi et al., 2010). Cerebral cortices from embryonic day 14.5 pups were dissected in Hank's balanced salt solution and mechanically dissociated using a micropipette. After centrifugation, cells were plated in a 60 mm culture dish coated with poly-L-ornithine (Sigma) and recombinant human fibronectin (R&D). Cells were cultured in a neural progenitor maintenance medium (NPMM) bullet kit (Lonza). The medium was changed every other day. After 4 days of expansion of NPCs, cells were replated and cultured with 100 μ M H_2O_2 or with and without EGF and FGF for induction of cell death. 100 μ M zVAD-fmk (BD bioscience) or 10 mM N-acetylcysteine (Sigma) were used as pan-caspase inhibitor or antioxidant, respectively. After 24 hr, cell survival was evaluated with immunostaining for cleaved caspase 3.

Statistics

Comparisons between groups were made by two-sided Student's t test. A p value less than 0.05 was considered significant.

ACCESSION NUMBERS

The GEO accession number for the tRNA sequencing data reported in this paper is GSE53391.

SUPPLEMENTAL INFORMATION

Supplemental Information includes Extended Experimental Procedures, seven figures, and three tables and can be found with this article online at <http://dx.doi.org/10.1016/j.cell.2014.02.058>.

AUTHOR CONTRIBUTIONS

E.K. and D.P. identified CLP1 mutation in patient cohorts, S.W. performed biochemical and Northern analysis, and H.S. performed mouse analysis.

ACKNOWLEDGMENTS

We thank the patients and families who participated in this study. We thank the CSF/PIF MRI imaging facility at the campus Vienna BioCenter. This work was supported in part by US National Institute of Neurological Disorders and Stroke (NINDS) grant R01NS058529 and US National Human Genome Research Institute (NHGRI) grant U54HG006542 to J.R.L. H.S. is supported in part by the fellowship of Astellas Foundation for Research on Metabolic Disorders and

The Mochida Memorial Foundation for Medical and Pharmaceutical Research. W.W. is supported by a K23NS078056 grant from the NINDS. M.G. is supported by grants from the DFG (FG885 and GRK 1459). J.M. and S.W. are supported by IMBA. J.M.P. is supported by an Advanced ERC grant and IMBA. L.M.F. is supported by a Career Development Award (1K23AI087821-01) from the NIAID. J.R.L. is a paid consultant for Athena Diagnostics, has stock ownership in 23andMe and Ion Torrent Systems, and is a coinventor on multiple United States and European patents related to molecular diagnostics for inherited neuropathies, eye diseases, and bacterial genomic fingerprinting. The Department of Molecular and Human Genetics at Baylor College of Medicine derives revenue from the clinical exome sequencing offered in the Medical Genetics Laboratory (MGL; <http://www.bcm.edu/geneticlabs/>).

Received: May 29, 2013

Revised: December 19, 2013

Accepted: February 21, 2014

Published: April 24, 2014

REFERENCES

- Adzhubei, I.A., Schmidt, S., Peshkin, L., Ramensky, V.E., Gerasimova, A., Bork, P., Kondrashov, A.S., and Sunyaev, S.R. (2010). A method and server for predicting damaging missense mutations. *Nat. Methods* 7, 248–249.
- Antonellis, A., Ellsworth, R.E., Sambuughin, N., Puls, I., Abel, A., Lee-Lin, S.Q., Jordanova, A., Kremensky, I., Christodoulou, K., Middleton, L.T., et al. (2003). Glycyl tRNA synthetase mutations in Charcot-Marie-Tooth disease type 2D and distal spinal muscular atrophy type V. *Am. J. Hum. Genet.* 72, 1293–1299.
- Bayat, V., Thiffault, I., Jaiswal, M., Tetreault, M., Donti, T., Sasarman, F., Bernard, G., Demers-Lamarche, J., Dicaire, M.J., Mathieu, J., et al. (2012). Mutations in the mitochondrial methionyl-tRNA synthetase cause a neurodegenerative phenotype in flies and a recessive ataxia (ARSAL) in humans. *PLoS Biol.* 10, e1001288.
- Bromberg, Y., Yachdav, G., and Rost, B. (2008). SNAP predicts effect of mutations on protein function. *Bioinformatics* 24, 2397–2398.
- Budde, B.S., Namavar, Y., Barth, P.G., Poll-The, B.T., Nürnberg, G., Becker, C., van Ruisven, F., Weterman, M.A., Fluiter, K., te Beek, E.T., et al. (2008). tRNA splicing endonuclease mutations cause pontocerebellar hypoplasia. *Nat. Genet.* 40, 1113–1118.
- Cassandrini, D., Biancheri, R., Tessa, A., Di Rocco, M., Di Capua, M., Bruno, C., Denora, P.S., Sartori, S., Rossi, A., Nozza, P., et al. (2010). Pontocerebellar hypoplasia: clinical, pathologic, and genetic studies. *Neurology* 75, 1459–1464.
- Chun, S., and Fay, J.C. (2009). Identification of deleterious mutations within three human genomes. *Genome Res.* 19, 1553–1561.
- Cooper, D.N., Ball, E.V., and Krawczak, M. (1998). The human gene mutation database. *Nucleic Acids Res.* 26, 285–287.
- Edvardson, S., Shaag, A., Kolesnikova, O., Gomeri, J.M., Tarassov, I., Einbinder, T., Saada, A., and Elpeleg, O. (2007). Deleterious mutation in the mitochondrial arginyl-transfer RNA synthetase gene is associated with pontocerebellar hypoplasia. *Am. J. Hum. Genet.* 81, 857–862.
- Gonzaga-Jauregui, C., Lotze, T., Jamal, L., Penney, S., Campbell, I.M., Pehlivan, D., Hunter, J.V., Woodbury, S.L., Raymond, G., Adesina, A.M., et al. (2013). Mutations in VRK1 associated with complex motor and sensory axonal neuropathy plus microcephaly. *JAMA Neurol.* 70, 1491–1498.
- Hanada, T., Weitzer, S., Mair, B., Bernreuther, C., Wainger, B.J., Ichida, J., Hanada, R., Orthofer, M., Cronin, S.J., Komnenovic, V., et al. (2013). CLP1 links tRNA metabolism to progressive motor-neuron loss. *Nature* 495, 474–480.
- Jordanova, A., Irobi, J., Thomas, F.P., Van Dijk, P., Meerschaert, K., Dewil, M., Dierick, I., Jacobs, A., De Vriendt, E., Guergueltcheva, V., et al. (2006). Disrupted function and axonal distribution of mutant tyrosyl-tRNA synthetase in dominant intermediate Charcot-Marie-Tooth neuropathy. *Nat. Genet.* 38, 197–202.
- Kumar, P., Henikoff, S., and Ng, P.C. (2009). Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. *Nat. Protoc.* 4, 1073–1081.
- Lancaster, M.A., Renner, M., Martin, C.A., Wenzel, D., Bicknell, L.S., Hurles, M.E., Homfray, T., Penninger, J.M., Jackson, A.P., and Knoblich, J.A. (2013). Cerebral organoids model human brain development and microcephaly. *Nature* 501, 373–379.
- Lee, J.W., Beebe, K., Nangle, L.A., Jang, J., Longo-Guess, C.M., Cook, S.A., Davisson, M.T., Sundberg, J.P., Schimmel, P., and Ackerman, S.L. (2006). Editing-defective tRNA synthetase causes protein misfolding and neurodegeneration. *Nature* 443, 50–55.
- Lupski, J.R., Belmont, J.W., Boerwinkle, E., and Gibbs, R.A. (2011). Clan genomics and the complex architecture of human disease. *Cell* 147, 32–43.
- McLaughlin, H.M., Sakaguchi, R., Liu, C., Igarashi, T., Pehlivan, D., Chu, K., Iyer, R., Cruz, P., Cherukuri, P.F., Hansen, N.F., et al.; NISC Comparative Sequencing Program (2010). Compound heterozygosity for loss-of-function lysyl-tRNA synthetase mutations in a patient with peripheral neuropathy. *Am. J. Hum. Genet.* 87, 560–566.
- Noble, C.G., Beuth, B., and Taylor, I.A. (2007). Structure of a nucleotide-bound Clp1-Pcf11 polyadenylation factor. *Nucleic Acids Res.* 35, 87–99.
- Olshen, A.B., Venkatraman, E.S., Lucito, R., and Wigler, M. (2004). Circular binary segmentation for the analysis of array-based DNA copy number data. *Biostatistics* 5, 557–572.
- Pehlivan, D., Hullings, M., Carvalho, C.M., Gonzaga-Jauregui, C.G., Loy, E., Jackson, L.G., Krantz, I.D., Deardorff, M.A., and Lupski, J.R. (2012). NIPBL rearrangements in Cornelia de Lange syndrome: evidence for replicative mechanism and genotype-phenotype correlation. *Genet. Med.* 14, 313–322.
- Phizicky, E.M., and Hopper, A.K. (2010). tRNA biology charges to the front. *Genes Dev.* 24, 1832–1860.
- Popow, J., Englert, M., Weitzer, S., Schleiffer, A., Mierzwa, B., Mechtler, K., Trowitzsch, S., Will, C.L., Luhrmann, R., Soll, D., et al. (2011). HSPC117 is the essential subunit of a human tRNA splicing ligase complex. *Science* 331, 760–764.
- Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M.A., Bender, D., Maller, J., Sklar, P., de Bakker, P.I., Daly, M.J., and Sham, P.C. (2007). PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am. J. Hum. Genet.* 81, 559–575.
- Renbaum, P., Kellerman, E., Jaron, R., Geiger, D., Segel, R., Lee, M., King, M.C., and Levy-Lahad, E. (2009). Spinal muscular atrophy with pontocerebellar hypoplasia is caused by a mutation in the VRK1 gene. *Am. J. Hum. Genet.* 85, 281–289.
- Roche, A.F., Mukherjee, D., Guo, S.M., and Moore, W.M. (1987). Head circumference reference data: birth to 18 years. *Pediatrics* 79, 706–712.
- Schaffer, A.E., Eggens, V.R.C., Caglayan, A.O., Reuter, M.S., Scott, E., Coufal, N.G., Silhavy, J.L., Xue, Y., Kayserili, H., Yasuno, K., et al. (2014). CLP1 founder mutation links tRNA splicing and maturation to cerebellar development and neurodegeneration. *Cell* 157, this issue, 651–663.
- Schwarz, J.M., Rödelberger, C., Schuelke, M., and Seelow, D. (2010). MutationTaster evaluates disease-causing potential of sequence alterations. *Nat. Methods* 7, 575–576.
- Shiraishi, H., Okamoto, H., Hara, H., and Yoshida, H. (2010). Alternative cell death of Apaf1-deficient neural progenitor cells induced by withdrawal of EGF or insulin. *Biochim. Biophys. Acta* 1800, 405–415.
- Siepel, A., Pollard, K.S., and Haussler, D. (2006). New methods for detecting lineage-specific selection. Apostolico, A., Guerra, C., Istrail, S., Pevzner, P., and Waterman, M., eds. *Proceedings of the 10th International Conference on Research in Computational Molecular Biology (RECOMB)*, 190–205.
- Valbuena, A., Vega, F.M., Blanco, S., and Lazo, P.A. (2006). p53 downregulates its activating vaccinia-related kinase 1, forming a new autoregulatory loop. *Mol. Cell. Biol.* 26, 4782–4793.

- Valbuena, A., Sanz-García, M., López-Sánchez, I., Vega, F.M., and Lazo, P.A. (2011). Roles of VRK1 as a new player in the control of biological processes required for cell division. *Cell. Signal.* **23**, 1267–1272.
- Vester, A., Velez-Ruiz, G., McLaughlin, H.M., Lupski, J.R., Talbot, K., Vance, J.M., Züchner, S., Roda, R.H., Fischbeck, K.H., Biesecker, L.G., et al.; NISC Comparative Sequencing Program (2013). A loss-of-function variant in the human histidyl-tRNA synthetase (HARS) gene is neurotoxic in vivo. *Hum. Mutat.* **34**, 191–199.
- Wan, J., Yourshaw, M., Mamsa, H., Rudnik-Schöneborn, S., Menezes, M.P., Hong, J.E., Leong, D.W., Senderek, J., Salman, M.S., Chitayat, D., et al. (2012). Mutations in the RNA exosome component gene EXOSC3 cause pontocerebellar hypoplasia and spinal motor neuron degeneration. *Nat. Genet.* **44**, 704–708.
- Weitzer, S., and Martinez, J. (2007). The human RNA kinase hCip1 is active on 3' transfer RNA exons and short interfering RNAs. *Nature* **447**, 222–226.